Form 13-F position report

ACORDA THERAPEUTICS INC

Reported by Saltoro Capital LP

ACOR 6 12/01/24 CUSIP 00484MAC0 Manager CIK 0001552059

Reported 1,500,000 shares, unchanged from the prior quarter.

Reported value 16.9%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 1.08% This manager · Q1 2024
Shares 1,500,000 Quarter-end amount reported
Reported value $855,000 Fair value at quarter end
Consecutive quarters held 13 Through Q1 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-03-31 1087000
2021-06-30 1110000
2021-09-30 1223000
2021-12-31 1223000
2022-03-31 1137000
2022-06-30 1110000
2022-09-30 1110000
2022-12-31 1124954
2023-03-31 991164
2023-06-30 981750
2023-09-30 877500
2023-12-31 731250
2024-03-31 855000
2024-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for ACORDA THERAPEUTICS INC held by Saltoro Capital LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2024 Reduced 0 -1,500,000 (-100.0%) 0 $0 2024-08-14
Q1 2024 Unchanged 1,500,000 0 (0.0%) 1.08% $855,000 2024-05-15
Q4 2023 Unchanged 1,500,000 0 (0.0%) 1.95% $731,250 2024-02-14
Q3 2023 Unchanged 1,500,000 0 (0.0%) 0.79% $877,500 2023-11-14
Q2 2023 Unchanged 1,500,000 0 (0.0%) 1.01% $981,750 2023-08-09
Q1 2023 Unchanged 1,500,000 0 (0.0%) 0.61% $991,164 2023-05-10
Q4 2022 Unchanged 1,500,000 0 (0.0%) 0.9% $1,124,954 2023-02-13
Q3 2022 Unchanged 1,500,000 0 (0.0%) 0.45% $1,110,000 2022-11-14
Q2 2022 Unchanged 1,500,000 0 (0.0%) 0.27% $1,110,000 2022-08-12
Q1 2022 Unchanged 1,500,000 0 (0.0%) 0.27% $1,137,000 2022-05-12
Q4 2021 Unchanged 1,500,000 0 (0.0%) 0.23% $1,223,000 2022-02-04
Q3 2021 Unchanged 1,500,000 0 (0.0%) 0.43% $1,223,000 2021-11-12
Q2 2021 Unchanged 1,500,000 0 (0.0%) 0.45% $1,110,000 2021-08-12
Q1 2021 New 1,500,000 +1,500,000 (0.0%) 0.27% $1,087,000 2021-05-14

Who else reported the position

9 managers reported ACORDA THERAPEUTICS INC for Q1 2024.

Managers reporting ACORDA THERAPEUTICS INC in Q1 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
HIGHBRIDGE CAPITAL MANAGEMENT LLC Unchanged 45,283,000 0 1.14% $31,018,855 13 qtrs
Davidson Kempner Capital Management LP Unchanged 0 0 0.3% $23,120,580 13 qtrs
UBS OCONNOR LLC Unchanged 30,000,000 0 0.57% $19,830,000 13 qtrs
SOROS FUND MANAGEMENT LLC Unchanged 27,951,000 0 0.26% $15,928,716 13 qtrs
CANYON CAPITAL ADVISORS LLC Unchanged 25,875,000 0 1.46% $13,703,814 13 qtrs
D E Shaw & Co Inc Unchanged 14,000,000 0 < 0.01% $8,155,000 13 qtrs
WELLS FARGO & COMPANY MN Unchanged 5,018,000 0 < 0.01% $2,858,755 13 qtrs
Saltoro Capital LP This report Unchanged 1,500,000 0 1.08% $855,000 13 qtrs
CONCOURSE FINANCIAL GROUP SECURITIES INC Unchanged 0 0 0 $0 13 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2024
Filed
May 15, 2024
Filing type
13F-HR
Position type
NOTE 6.000%12/0

Voting authority reported

Sole
1,500,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.